Drug Pricing
Our work in Drug Pricing
-
Making Progress in Cancer Diagnostics: Clinical Practice and Policy
Join the Health, Medicine and Society Program of the Aspen Institute and the USC Schaeffer Center for a webinar on new clinical advances in cancer screening and the policy issues surrounding access to and adoption of these advances.
-
Variation in Generic Dispensing Rates in Medicare Part D
Generic use has increased over time in Medicare Part D, but substantial variation across plans persists in a number of common classes.
Categorized in -
Sharing Drug Rebates With Medicare Part D Patients: Why And How
The percentage of total Medicare Part D drug spending offset by rebates on branded drugs increased from 11% in 2010 to 25% in 2018.
Categorized in -
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for advances in Alzheimer’s disease made in 2001 and projects future breakthroughs over the next 20 years.
Categorized in -
Ten Actions For Better Post-Pandemic Healthcare In The United States
What changes should be made now to the U.S. healthcare system to make it better when things return to a new normal, and, in the event of future pandemics.
Categorized in -
Are We Gearing Up for a Drug Rebate Rule Instant Replay?
The so-called “rebate rule” was reported dead in 2019. Here’s why that may not be entirely true.
Categorized in -
Uptake of Infliximab Biosimilars Among the Medicare Population
Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.
Categorized in -
California Leads in Public Investment in Biomedical Innovation and It Is Beginning to Show Returns
Schaeffer Center research indicates public investment into biomedical innovation yields substantial economic and social return in California.
Categorized in -
The Economic Case for Public Investment in Stem Cell Research
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
Categorized in -
Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the U.S.
In a study published in Pharmacoeconomics, we find multiple blockbuster drugs have received exclusivity of more than 10 years through the Orphan Drug Act, thereby delaying access to generic/biosimilar equivalents.
Categorized in